Decibel Therapeutics has been granted a patent for hypertonic pharmaceutical compositions containing anti-platinum chemoprotectant agents and gelling agents. The compositions have a calculated osmolarity of 3,000-7,000 mOsm/L. The patent also covers methods of medical use for these compositions. GlobalData’s report on Decibel Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Decibel Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Decibel Therapeutics, Recombinant AAV gene therapy was a key innovation area identified from patents.

Hypertonic pharmaceutical composition for anti-platinum chemoprotection

Source: United States Patent and Trademark Office (USPTO). Credit: Decibel Therapeutics Inc

A recently granted patent (Publication Number: US11857567B2) discloses a hypertonic pharmaceutical composition designed to prevent or mitigate platinum-induced ototoxicity in subjects. The composition has a calculated osmolarity ranging from 3,000 to 7,000 mOsm/L and includes 1M-2M of an anti-platinum chemoprotectant agent, a gelling agent, and an optional tonicity agent. The osmolarity is calculated based on the chemoprotectant agent and tonicity agent, if present, with a preferred range of 3,000-5,000 mOsm/L. The anti-platinum chemoprotectant agent can be various substances such as sodium thiosulfate, amifostine, or glutathione, while the gelling agent can include hyaluronan, polyethylene glycol, or cellulose derivatives.

The method of administration involves delivering the hypertonic pharmaceutical composition intratympanically or transtympanically to the round window of the subject. This method aims to protect against platinum-induced ototoxicity caused by platinum-based antineoplastic agents. The composition can be administered before or after the platinum-based agent through a different route. The patent also covers the preparation method of the composition, involving mixing the chemoprotectant agent, gelling agent, and optional tonicity agent with a liquid solvent to achieve the desired hypertonic formulation. The patent emphasizes the importance of the specific concentrations and components in the composition to effectively prevent or mitigate platinum-induced ototoxicity.

To know more about GlobalData’s detailed insights on Decibel Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies